查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924704

镁合金血管支架市场：按支架类型、涂层、部署机制、应用和最终用户划分－2026-2032年全球预测

Mg Alloy Vascular Scaffold Market by Scaffold Type, Coating, Deployment Mechanism, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年镁合金血管支架市场价值为 2.1255 亿美元，预计到 2026 年将成长至 2.4746 亿美元，预计到 2032 年将达到 5.8376 亿美元，复合年增长率为 15.52%。

关键市场统计数据
基准年 2025 2.1255亿美元
预计年份：2026年 2.4746亿美元
预测年份 2032 5.8376亿美元
复合年增长率 (%) 15.52%

简明扼要、权威地介绍了镁合金血管支架技术、临床证据以及血管介入治疗领域商业决策者的策略考量。

镁合金血管支架作为创新选择，在介入医学领域再次受到关注。它结合了临时机械支撑和渐进式生物吸收，从而减少了支架在血管内的长期留置时间。这些支架旨在平衡血管癒合过程中的急性机械性能和可控的溶解过程，最大限度地减少慢性异物反应。随着支架设计的不断发展，合金冶金、表面工程和药物涂层策略的结合，使得支架的降解速率更加可预测，并改善了内皮细胞的反应。

关键技术、临床工作流程、监管协调以及基于价值的采购动态正在共同重塑生物可吸收镁血管支架的采用路径。

过去几年，我们观察到一系列变革性变化，这些变化正在重新定义人们对血管支架解决方案的预期。合金成分和微观结构细化的创新，使得材料具有更高的强度重量比和更可预测的腐蚀行为，从而能够设计出既满足临时血管支撑需求又不影响生物相容性的支架。同时，表面改质技术和薄膜药物涂层的进步，促进了内皮化并抑制了新生内膜增生，缩小了可生物吸收支架和永久性支架之间的性能差距。

2025年医疗设备贸易关税调整将改变供应链、在地化生产和采购趋势，进而影响定价、市场进入和策略规划。

预计的贸易政策转变，包括2025年生效的关税，将为镁合金支架价值链上的相关人员和策略方面的考量。对医疗设备组件或成品征收关税可能会增加依赖跨境供应链的製造商的到岸成本，迫使采购团队重新评估供应商选择、采购地理和库存策略。实际上，不断上涨的进口关税将迫使製造商实现在地化生产、对本地供应商进行资格认证，或调整材料清单（BOM），以在维持临床效能的同时降低成本风险。

针对支架类型、临床应用、终端用户环境、涂层技术和部署机制等各个方面，提供可操作的见解，以指导产品定位和临床策略。

了解需求驱动因素需要对产品属性、临床应用案例、医疗服务环境、涂层策略和部署机制进行详细细分，因为这些因素都会影响临床结果和采购优先顺序。按支架类型划分，竞争格局包括裸镁结构、旨在刺激癒合反应的生物活性支架以及旨在释放抗增殖药物的药物释放型支架。药物释放型支架可根据活性成分进一步细分：生物活性成分包括Biolimus、Everolimus和Sirolimus，每种成分都具有不同的药物动力学和组织相互作用特征，从而影响血管再阻塞控制和内皮恢復时间。

区域监管差异、临床基础设施和供应链因素如何影响美洲、欧洲、中东和非洲以及亚太地区的差异化打入市场策略

区域趋势对监管路径、临床医生采纳和供应链设计有显着影响，美洲、欧洲、中东和非洲以及亚太地区的情况各有不同。在美洲，临床领导者优先考虑长期血管癒合结果的证据和简化的报销机制，这迫使器械开发商将试验终点与支付方的价值框架和医院采购标准相一致。同时，本地生产能力和监管时间表将影响企业扩大商业性营运规模的速度。

竞争优势、合作模式、临床应用路径，以及主要企业实现差异化并加速镁合金血管支架解决方案市场接受度的能力。

镁合金血管支架市场的竞争格局呈现出多元化的特点，既有成熟的心血管器械製造商，也有专注于生物可吸收材料的专业研发公司，以及从合金生产到成品全产业链的垂直整合型企业。主要企业往往重视开发平臺，整合冶金、表面工程和药物製剂等领域的专业知识，以实现差异化的降解特性和更佳的安全性。材料科学团队、涂层专家和临床研究机构之间的策略联盟加速了从研究到临床应用的转化。

一项切实可行的跨职能策略，结合材料创新、临床证据项目、供应链韧性和市场进入途径，以加速永续应用。

产业领导者应优先考虑一种协作策略，该策略应平衡材料科学的投资与实际的临床和商业性努力。首先，他们将资源投入到迭代合金优化和表面工程中，以减少降解曲线的变异性并提高生物相容性。这些技术投资，结合以机制终点为重点的可靠的临床前和早期临床试验，将建构更强有力的证据基础。同时，企业应设计临床医生参与计划，透过研讨会、影像引导治疗通讯协定和指导等方式规范植入技术，从而最大限度地减少早期实施阶段的技术差异。

我们采用透明的混合方法，结合临床医师访谈、材料科学文献、监管沟通和供应链分析，提供实证策略指导。

本执行摘要的调查方法融合了原始定性资料和有针对性的二手证据综合分析，旨在建立一个临床支持且平衡的观点。原始数据包括对介入性心臟病专家、介入神经放射学、血管外科医生、采购人员和监管顾问的结构化访谈，以了解他们对器械性能的真实认知、手术推广障碍以及报销方面的考虑。这些访谈旨在揭示器械的运作机制、临床医生的工作流程偏好以及影响医院采购决策的因素。

策略整合强调技术检验、临床医生培训、法规遵循和永续商业化是实现长期临床和商业性成功的关键。

镁合金血管支架在介入治疗中占有重要的地位，它能够提供暂时的机械支撑，并透过可控吸收来实现长期的异物负荷减轻。合金技术的进步、涂层技术的应用、最佳手术操作规范以及不断完善的监管路径之间的相互作用，正在创造一个充满活力的环境，在这个环境中，那些能够整合卓越技术、严谨的临床证据和切实可行的商业化策略的企业将取得成功。临床医生培训、影像引导下的留置技术以及完善的上市后资料收集，将在证明支架的持续安全性和功能恢復方面发挥关键作用。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 镁合金血管支架市场（依支架类型划分）

  • 熊
  • 生物活性
  • 药物释放型型
    • Biolimus洗脱型
    • Everolimus洗脱
    • Sirolimus洗脱

9. 镁合金血管支架市场（依涂层划分）

  • 未涂层
  • 聚合物涂层
    • 可生物降解聚合物
    • 耐用聚合物

第十章：镁合金血管支架市场发展机制分析

  • 气球膨胀类型
  • 自膨胀

第十一章 镁合金血管支架市场（按应用领域划分）

  • 冠状动脉
    • 急性心肌梗塞
    • 稳定性心绞痛
  • 神经血管
    • 动脉瘤
    • 缺血性中风
  • 外围
    • 下肢动脉
    • 肾动脉

第十二章 镁合金血管支架市场（依最终用户划分）

  • 门诊手术中心
  • 心臟导管检查室
  • 医院

13. 镁合金血管支架市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 镁合金血管支架市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国镁合金血管支架市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国镁合金血管支架市场

第十七章 中国镁合金血管支架市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AmsinoMed Medical Co., Ltd
  • Arterial Remodeling Technologies, Inc.
  • Biotronik SE & Co. KG
  • Elixir Medical Corporation
  • FY MedTech
  • Magnesium Elektron Ltd.
  • Q3 Medical Devices
  • QualiMed, Inc.
  • Shanghai Pulin Medical Technology Co., Ltd.
  • SINOMED Co., Ltd.
Product Code: MRR-7A380DA7C43B

The Mg Alloy Vascular Scaffold Market was valued at USD 212.55 million in 2025 and is projected to grow to USD 247.46 million in 2026, with a CAGR of 15.52%, reaching USD 583.76 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 212.55 million
Estimated Year [2026] USD 247.46 million
Forecast Year [2032] USD 583.76 million
CAGR (%) 15.52%

Concise authoritative framing of magnesium alloy vascular scaffold technologies, clinical rationale, and strategic considerations for executive decision-makers in interventional vascular care

Magnesium alloy vascular scaffolds are re-emerging as a transformative option in interventional medicine, blending temporary mechanical support with progressive bioresorption to reduce long-term device presence in the vasculature. These scaffolds seek to deliver a balance between acute mechanical performance during vessel healing and a controlled dissolution profile that minimizes chronic foreign body reaction. As device design evolves, the convergence of alloy metallurgy, surface engineering, and drug coating strategies is enabling more predictable degradation kinetics and improved endothelial responses.

This executive summary synthesizes current technological advancements, clinical adoption dynamics, regulatory trajectories, and commercial forces shaping the landscape. It is informed by recent peer-reviewed evidence, regulatory communications, and observed shifts in hospital procurement preferences. The intent is to provide senior leaders with a clear narrative of how magnesium alloy scaffold technologies are positioned relative to permanent metallic stents and polymeric bioresorbable scaffolds, and to highlight strategic inflection points for portfolio development, clinical trial design, and market access planning.

Throughout the document, discussion emphasizes mechanism-driven performance attributes, clinician adoption drivers, and the interplay between reimbursement environments and hospital infrastructure. The goal is to equip decision-makers with actionable context that informs R&D prioritization, clinical engagement strategies, and partnership selection in a rapidly evolving interventional device ecosystem.

Critical technology, clinical workflow, regulatory adjustments, and value-based purchasing dynamics that are jointly reshaping adoption pathways for bioresorbable magnesium vascular scaffolds

The past several years have witnessed a sequence of transformative shifts that are recalibrating expectations for vascular scaffolding solutions. Innovations in alloy composition and microstructure refinement have yielded materials with improved strength-to-weight ratios and more predictable corrosion behavior, enabling designs that better match transient vessel support requirements without compromising biocompatibility. Parallel advances in surface modification techniques and thin-film drug coatings have enhanced endothelialization while mitigating neointimal proliferation, narrowing the performance gap between bioresorbable and permanent devices.

Clinical methodology has evolved concurrently, with interventionalists adopting imaging-guided implantation workflows and more selective lesion preparation strategies that optimize scaffold apposition and reduce acute mechanical complications. Health systems are responding by investing in cath lab imaging capabilities and training that support adoption of next-generation scaffolds. Regulatory frameworks in major markets are also adapting, increasingly accommodating iterative device improvements through targeted clinical pathways and post-market surveillance expectations that allow companies to refine materials and coatings while maintaining patient safety oversight.

Commercial dynamics are shifting as hospitals and payors evaluate total episode-of-care value rather than the device price alone. This broader perspective creates opportunities for stakeholders who can demonstrate reductions in downstream complication rates, shorter recovery times, or meaningful improvements in patient-reported outcomes. The net effect of these technological, clinical, regulatory, and commercial forces is a landscape characterized by accelerated innovation cycles, closer collaboration between device developers and clinician leaders, and an expectation that safety and long-term vascular healing will determine sustainable adoption.

How 2025 tariff shifts on medical device trade create supply chain, manufacturing localization, and procurement dynamics that materially affect pricing, access, and strategic planning

Anticipated trade policy shifts, including tariff measures enacted in 2025, introduce a layered set of operational and strategic considerations for stakeholders in the magnesium alloy scaffold value chain. Tariffs on medical device components or finished devices can increase landed costs for manufacturers that rely on cross-border supply chains, prompting procurement teams to reassess supplier selection, sourcing geographies, and inventory strategies. In practice, rising import duties exert pressure on manufacturers to localize manufacturing, qualify regional suppliers, or reconfigure bill-of-materials to mitigate cost exposure while preserving clinical performance.

Clinicians and hospital administrators will experience indirect effects through procurement cycles and capital planning. Hospitals may accelerate conversations with suppliers about total cost of care and value-based contracting to offset potential price adjustments. Device developers with vertically integrated manufacturing or regional production capacity will have a relative advantage as they can insulate pricing and delivery timelines from tariff volatility. Additionally, tighter margins can influence how companies allocate investment across clinical evidence generation and post-market surveillance, sometimes favoring partnerships that share trial or registry costs.

From a regulatory and reimbursement standpoint, tariffs can alter the economic calculus for market entry strategies, altering timelines for establishing local distributor networks versus direct-market operations. It is essential for industry leaders to conduct scenario planning that models supply chain rerouting, contract renegotiation, and capital investment in regional production to maintain competitiveness and ensure uninterrupted access to innovative scaffold technologies for patients.

Actionable insights across scaffold type, clinical applications, end-user settings, coating technologies, and deployment mechanisms to guide product positioning and clinical strategy

Understanding demand drivers requires granular segmentation across product attributes, clinical use-cases, provider settings, coating strategies, and deployment mechanisms, each of which shapes clinical outcomes and procurement priorities. By scaffold type, the competitive field includes bare magnesium constructs, bioactive variants engineered to stimulate healing responses, and drug-eluting scaffolds designed to deliver antiproliferative agents; the drug-eluting category further differentiates by the active compound, where biolimus, everolimus, and sirolimus each carry distinctive pharmacokinetic and tissue interaction profiles that influence restenosis control and endothelial recovery timelines.

Application-specific insights reveal divergent clinical needs across coronary, neurovascular, and peripheral territories. Coronary use splits along acute presentation versus stable disease, where acute myocardial infarction cases demand immediate mechanical reliability and predictable resorption, while stable angina interventions prioritize long-term vessel patency and patient quality of life. Neurovascular applications address aneurysm repair and ischemic stroke adjunctive support, requiring scaffolds that balance radial support with minimal inflammatory footprint in delicate cerebral vessels. Peripheral indications, covering lower limb artery and renal artery treatments, impose unique mechanical flexibility and corrosion-resistance requirements because of differing hemodynamic stresses and vessel sizes.

End-user settings shape adoption patterns and service-level expectations; ambulatory surgical centers, cardiac catheterization labs, and hospitals each have distinct imaging capabilities, clinician expertise levels, and purchasing frameworks that affect which scaffold profiles are preferred. Coating strategy plays a pivotal role in matching device behavior to clinical objectives, with non-coated scaffolds offering simplicity and faster resorption and polymer-coated options-biodegradable or durable polymers-enabling controlled drug release and modified surface interactions. The deployment mechanism, whether balloon expandable or self-expanding, further determines procedural workflow and lesion selection, affecting clinician training needs and inventory management. Integrating these segmentation axes into product development and commercial plans enables more precise targeting of clinical evidence and reimbursement positioning.

How regional regulatory variance, clinical infrastructure, and supply chain considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated market entry strategies

Regional dynamics exert a pronounced influence on regulatory pathways, clinician adoption, and supply chain design, with distinct considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical leaders emphasize evidence demonstrating long-term vascular healing outcomes and streamlined reimbursement mechanisms, prompting device developers to align trial endpoints with payer value frameworks and hospital procurement criteria. Meanwhile, local manufacturing capabilities and regulatory timelines influence how quickly firms can scale commercial operations.

Across Europe, the Middle East & Africa, diversity in regulatory regimes and hospital infrastructure drives a need for adaptable market access approaches. Some markets prioritize centralized clinical data and robust post-market registries, while others prioritize rapid adoption if clinical benefits align with existing practice. In Asia-Pacific, rapid investment in interventional cardiology infrastructure, coupled with large patient volumes and competitive domestic manufacturers, creates both opportunity and pressure; device designers must consider cost-sensitive procurement while also addressing clinician demands for advanced imaging and implantation tools.

These regional contrasts demand tailored commercialization blueprints: a unified global value proposition must be complemented by region-specific evidence generation, supply chain localization strategies, and clinical affairs programs that resonate with local key opinion leaders and regulatory expectations. Strategic partnerships with regional distributors, clinical centers, and manufacturing partners can accelerate market preparedness and mitigate tariff, logistic, or regulatory hurdles.

Competitive dynamics, collaboration models, clinical adoption pathways, and capabilities that distinguish leading companies and accelerate acceptance of magnesium alloy vascular scaffold solutions

The competitive landscape for magnesium alloy vascular scaffolds is characterized by a mix of established cardiovascular device manufacturers, specialized developers focused on bioresorbable materials, and vertically integrated firms that control alloy production through to finished devices. Companies leading technological advances often emphasize integrated R&D pipelines that combine metallurgy, surface engineering, and drug formulation expertise to deliver differentiated degradation profiles and improved safety signals. Strategic alliances between material science groups, coating specialists, and clinical research organizations accelerate translation from bench to bedside.

Clinical adoption often follows a pattern where early clinical adopters at high-volume centers validate procedural workflows and generate peer-reviewed evidence. Manufacturers that invest in targeted investigator-initiated studies and multi-center registries gain credibility with clinicians and payors by demonstrating procedural reproducibility and safety across diverse lesion types. At the same time, firms that offer comprehensive procedural support-training, imaging protocols, and proctoring-reduce clinician learning curves and enhance the probability of favorable clinical outcomes.

From a commercial perspective, companies that demonstrate supply chain resilience, local manufacturing options, and flexible pricing arrangements typically secure preferred access within hospital procurement systems. Given the complexity of bringing bioresorbable scaffold technologies to market, many firms pursue partnerships or licensing agreements to combine clinical evidence generation capacity with established distribution networks and clinician relationships.

Practical cross-functional strategies combining material innovation, clinical evidence programs, supply chain resilience, and market access pathways to accelerate sustainable adoption

Industry leaders should prioritize a coordinated strategy that balances material science investment with pragmatic clinical and commercial initiatives. First, allocating resources to iterative alloy optimization and surface engineering will reduce variability in degradation profiles and improve biocompatibility; coupling these technical investments with robust preclinical and early clinical studies focused on mechanism-based endpoints will create a stronger evidentiary foundation. Simultaneously, companies should design clinician engagement programs that standardize implantation technique through hands-on workshops, image-guided procedural protocols, and proctoring to minimize technical variability during early adoption.

Second, supply chain resilience must be elevated as a strategic objective. Scenario planning should assess the benefits of regional manufacturing or dual-sourcing strategies to insulate operations from tariff shifts and logistic disruptions. Negotiating value-based contracts and risk-sharing arrangements with health systems can align incentives around long-term patient outcomes, and these arrangements should be supported by real-world evidence generation through registries and post-market studies. Finally, pursue targeted partnerships for market entry that combine local regulatory expertise with distribution capability, enabling flexible commercialization models that respond to regional payer landscapes and clinician preferences.

Implementing this multi-dimensional approach will require cross-functional coordination across R&D, clinical affairs, regulatory, manufacturing, and commercial teams, but it also offers a practical pathway to accelerate adoption while managing cost and access risks inherent in complex device categories.

Transparent mixed-methods approach combining clinician interviews, materials science literature, regulatory communications, and supply chain analysis to inform evidence-based strategic guidance

The research methodology underpinning this executive summary blends primary qualitative inputs with targeted secondary evidence synthesis to generate a balanced, clinically anchored perspective. Primary inputs include structured interviews with interventional cardiologists, neurointerventional specialists, vascular surgeons, procurement leaders, and regulatory advisers to capture real-world device performance perceptions, procedural adoption barriers, and reimbursement considerations. These interviews were designed to surface mechanistic insights, clinician workflow preferences, and criteria that influence hospital purchasing decisions.

Secondary evidence was assembled from peer-reviewed clinical studies, regulatory agency communications, device labeling information, materials science literature on magnesium alloys and coatings, and publicly available clinical registry outcomes. Where possible, triangulation was applied to corroborate claims across data sources and to contextualize device performance relative to established clinical endpoints. In addition, supply chain analyses incorporated trade and logistics publications and public filings to evaluate manufacturing footprints and potential exposure to tariff and import risks.

The methodological approach emphasizes transparency about data provenance, the limitations of available evidence, and the need for ongoing post-market surveillance to validate early clinical findings. Readers should interpret recommendations as strategic guidance grounded in current clinical practice and material science developments rather than definitive predictions about future market trajectories.

Strategic synthesis emphasizing technical validation, clinician training, regulatory alignment, and resilient commercialization as keys to long-term clinical and commercial success

Magnesium alloy vascular scaffolds occupy an important niche within interventional therapy, offering the promise of temporary mechanical support followed by controlled resorption that reduces long-term foreign body burden. The interplay of alloy advancements, coating technologies, procedural best practices, and evolving regulatory pathways creates a dynamic environment where successful players will be those who integrate technical excellence with rigorous clinical evidence and pragmatic commercialization strategies. Clinician training, imaging-supported implantation techniques, and robust post-market data capture will be central to demonstrating durable safety and functional recovery.

Organizational readiness to respond to trade policy shifts, supply chain interruptions, and regional regulatory nuance will also determine how quickly innovations translate into routine clinical practice. Companies that align R&D priorities with clear clinical endpoints, invest in real-world evidence generation, and develop flexible manufacturing and distribution strategies will be better positioned to navigate complexity. Ultimately, patient-centric outcomes-reduced complications, restored vessel function, and improved quality of life-should remain the north star for product development and commercialization choices.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Mg Alloy Vascular Scaffold Market, by Scaffold Type

  • 8.1. Bare
  • 8.2. Bioactive
  • 8.3. Drug Eluting
    • 8.3.1. Biolimus Eluting
    • 8.3.2. Everolimus Eluting
    • 8.3.3. Sirolimus Eluting

9. Mg Alloy Vascular Scaffold Market, by Coating

  • 9.1. Non Coated
  • 9.2. Polymer Coated
    • 9.2.1. Biodegradable Polymer
    • 9.2.2. Durable Polymer

10. Mg Alloy Vascular Scaffold Market, by Deployment Mechanism

  • 10.1. Balloon Expandable
  • 10.2. Self Expanding

11. Mg Alloy Vascular Scaffold Market, by Application

  • 11.1. Coronary
    • 11.1.1. Acute Myocardial Infarction
    • 11.1.2. Stable Angina
  • 11.2. Neurovascular
    • 11.2.1. Aneurysm
    • 11.2.2. Ischemic Stroke
  • 11.3. Peripheral
    • 11.3.1. Lower Limb Artery
    • 11.3.2. Renal Artery

12. Mg Alloy Vascular Scaffold Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cardiac Catheterization Labs
  • 12.3. Hospitals

13. Mg Alloy Vascular Scaffold Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Mg Alloy Vascular Scaffold Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Mg Alloy Vascular Scaffold Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Mg Alloy Vascular Scaffold Market

17. China Mg Alloy Vascular Scaffold Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AmsinoMed Medical Co., Ltd
  • 18.6. Arterial Remodeling Technologies, Inc.
  • 18.7. Biotronik SE & Co. KG
  • 18.8. Elixir Medical Corporation
  • 18.9. FY MedTech
  • 18.10. Magnesium Elektron Ltd.
  • 18.11. Q3 Medical Devices
  • 18.12. QualiMed, Inc.
  • 18.13. Shanghai Pulin Medical Technology Co., Ltd.
  • 18.14. SINOMED Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOACTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOACTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOACTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIOLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NON COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NON COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NON COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DURABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DURABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DURABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY LOWER LIMB ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY LOWER LIMB ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY LOWER LIMB ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY RENAL ARTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY RENAL ARTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY RENAL ARTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CATHETERIZATION LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CATHETERIZATION LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CATHETERIZATION LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 189. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 190. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 191. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 194. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 195. GCC MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 221. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 222. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 223. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 224. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 226. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 227. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 228. G7 MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 232. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 233. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 234. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 235. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 238. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 239. NATO MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DRUG ELUTING, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY DEPLOYMENT MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY NEUROVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA MG ALLOY VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)